

CLINICAL PRACTICE GUIDELINE

Human milk and breastfeeding during ketogenic diet therapy in infants with epilepsy: Clinical practice guideline

Elles van der Louw¹  | Petra Trimmel-Schwahofer^{2,3} | Anita Devlin^{4,5} | Marisa Armeno⁶ | Lindsey Thompson⁷ | J. Helen Cross⁸  | Stéphane Auvin^{3,9,10,11}  | Anastasia Dressler^{2,3} 

¹Department of Internal Medicine, Division of Dietetics, Erasmus MC University Medical Center, Rotterdam, the Netherlands

²Department of Pediatrics and Adolescent Medicine, Medical University Vienna, Vienna, Austria

³European Reference Network, EpiCARE

⁴Paediatric Neurology, Great North Children's Hospital, Newcastle upon Tyne, UK

⁵Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK

⁶Department of Nutrition, Hospital de Pediatría Prof. Dr. J.P. Garrahan, Buenos Aires, Argentina

⁷Children's Mercy Hospital and Clinics, Kansas City, Missouri, USA

⁸UCL NIHR BRC Great Ormond Street Institute of Child Health, Great Ormond Street Hospital for Children NHS Trust, London, UK

⁹APHP, Service de Neurologie Pédiatrique, Hôpital Robert Debré, Paris, France

¹⁰Université Paris-Cité, INSERM Neuro Diderot, Paris, France

¹¹Institut Universitaire de France (IUF), Paris, France

Correspondence

Elles van der Louw, Department of Internal Medicine, Division of Dietetics, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands.
Email: e.vanderlouw@erasmusmc.nl

Abstract

Ketogenic diet therapy (KDT) is a safe and effective treatment for epilepsy and glucose transporter type 1 (GLUT1) deficiency syndrome in infancy. Complete weaning from breastfeeding is not required to implement KDT; however, breastfeeding remains uncommon. Barriers include feasibility concerns and lack of referrals to expert centres. Therefore, practical strategies are needed to help mothers and professionals overcome these barriers and facilitate the inclusion of breastfeeding and human milk during KDT. A multidisciplinary expert panel met online to address clinical concerns, systematically reviewed the literature, and conducted two international surveys to develop an expert consensus of practical recommendations for including human milk and breastfeeding in KDT. The need to educate about the nutritional benefits of human milk and to increase breastfeeding rates is emphasized. Prospective real-world registries could help to collect data on the implementation of breastfeeding and the use of human milk in KDT, while systematically including non-seizure-related outcomes, such as quality of life, and social and emotional well-being, which could improve outcomes for infants and mothers.

Ketogenic diet therapy (KDT) is a well-established treatment for drug-resistant epilepsy, glucose transporter type 1 (GLUT1) deficiency syndrome, and specific epilepsy syndromes such as infantile epileptic spasms syndrome in early infancy.^{1–4} Data have shown that KDT is feasible, effective, and safe in this age group.^{5–11} Readily available

ketogenic formulae have facilitated the introduction of KDT in young infants before the introduction of solid food, when compliance is higher. Compared with older children, dropout rates are lower,⁴ treatment duration is shorter (between 10 and 13 months),⁵ and effectiveness rates are high. However, randomized controlled trials in

Abbreviations: GLUT1, glucose transporter type 1; KDT, ketogenic diet therapy.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2024 The Authors. *Developmental Medicine & Child Neurology* published by John Wiley & Sons Ltd on behalf of Mac Keith Press.

this age group to demonstrate efficacy in specific epilepsy syndromes and aetiologies are rare and urgently needed.¹² A recent randomized controlled trial has shown that KDT was as effective as antiseizure medication in drug-resistant epilepsy in this age group.¹³ This study showed that the odds ratios of achieving seizure freedom after 8 weeks and improving communication, socialization, and overall health scores were slightly higher in the group receiving KDT than in that receiving antiseizure medication, with a similar proportion experiencing at least one serious adverse event.

Current guidelines on KDT in infants⁸ suggest a gradual introduction and individual escalation of 'classic' KDT with a fixed fat:non-fat ratio to a maximum of 3:1. Fasting and fluid restriction are not advised in this age group.^{9,14,15} The fat:non-fat ratio can be adjusted according to the clinical condition of the child and the individual ketosis level. Consequently, lower fat:non-fat ratios allow higher carbohydrate intake which can facilitate the inclusion of human milk and breastfeeding into KDT.¹⁶

However, current international guidelines^{8,9} do not contain recommendations for including human milk and breastfeeding as part of KDT, in contrast to other diseases such as phenylketonuria or other inborn errors of metabolism.¹⁷⁻¹⁹

Human milk is considered the ideal food and criterion standard for newborn babies. On the basis of the proven short- and long-term benefits of human milk and breastfeeding both for the infant and for the mother, the American Academy of Pediatrics reiterated its recommendations in 2022: 'Exclusive breastfeeding for approximately 6 months, followed by continued breastfeeding with the introduction of complementary foods, continued for 1 year or more, each, as desired by mother and infant'.²⁰⁻²² These recommendations are in line with those of the World Health Organization²³ and its current guideline. The aim is to give increased support to health-care facilities that provide maternity and newborn-baby care, to protect, promote, and support breastfeeding.²⁴

Given the lack of recommendations on the inclusion of human milk and breastfeeding in KDT, our aim was to provide practical recommendations based on expert consensus. Our methods associated a narrative review completed by an international survey about the inclusion of human milk in infant KDT.

METHOD

A working group of five experts (ADre, EvdL, PT-S, SA, JHC: i.e. three paediatric neurologists and two registered dietitians) already involved in the ketogenic diet guidelines for infants with drug-resistant epilepsy⁸ met online to discuss issues arising from the clinical management of breastfed infants on KDT.

On the basis of the limited data already published, the survey was conducted rather than a Delphi panel to base our expert opinion on current clinical practice more than consensual opinion. Similar approaches have been used

What this paper adds

- Human milk and breastfeeding can be incorporated safely into ketogenic diet therapy.
- With expert guidance, human milk and breastfeeding do not reduce diet effectiveness.
- We show two strategies for clinical practice to include human milk.
- Mothers can be encouraged to continue breastfeeding.

previously for expert consensual recommendations on the use of KDT in infants⁸ and the parenteral administration of KDT.²⁵

Literature review

A narrative review of the literature was conducted using the National Library of Medicine. Three searches were done using the following keywords: 'breastfeeding AND ketogenic diet', 'human milk AND ketogenic diet', and 'breast milk AND ketogenic diet', last updated on 5th April 2023. Search queries 'human milk AND ketogenic diet' returned fewer results ($n=7$) but completely overlapped with search 'breast milk AND ketogenic diet', so we used results from search 'breast milk AND ketogenic diet'. However, we decided to use the standardized term 'human milk' throughout the text, as recently suggested.²⁶ English-language articles were included as there were no articles found in other languages (as of 30th January 2024). Abstracts were screened to identify any original papers on the use of human milk during KDT in infants. The selection process for the papers included in this review is shown in [Figure S1](#).

International survey

An international survey consisting of an online questionnaire in four languages (English, French, German, and Italian) was distributed to an international group of dietitians and paediatric neurologists by Matthews Friends UK, the Ketogenic Diet National Working Group of Netherlands/Flanders, the Ketogenic Diet Network of German-Speaking Countries, the Ketogenic Dietician Research Network of the UK, and the 'Ketogenic ListServ'. Conducting an international survey allowed the experts to base their recommendations on facts more than by collecting consensual opinion from a Delphi panel that might be disconnected from daily clinical practice.

The digital surveys sent in 2021 and 2023 (updated shorter version) are included in Appendices [S1](#) and [S2](#). The first questionnaire consisted of 22 questions on patient type, indications, diet composition, diet application,

ketone levels, outcomes, benefits and challenges of human milk use, reasons for discontinuing KDT, and maternal diet. The second questionnaire consisted of five questions on KDT indications, dietary application, and maternal diet.

Practical recommendations

The literature review and survey responses were used to formulate an expert consensus about practical recommendations for the inclusion of human milk and breastfeeding in KDT. The expert group comprised the authors of this paper.

RESULTS

Narrative review of literature

Five original papers reporting the use of human milk in KDT for infants were found (Figure S1). These included three clinical case series of infants treated by KDT including human milk,^{27–29} one comparative study of infants treated by KDT including human milk compared with infants not fed human milk,¹⁶ and one case report of a lactating mother who underwent KDT herself, introduced gradually, to treat her infant who had drug-resistant epilepsy with ketogenic human milk.^{30,31} Detailed data are shown in Table S1.

International survey

Survey participants

On the basis of the small number of infants on KDT with human milk ($n=35$) reported in the literature, we expected the experience with the use of human milk during KDT to be limited. Thirty-six expert centres from 17 different countries (Austria, Australia, Argentina, Belgium, Brazil, France, Chile, Germany, Ireland, Italy, Mexico, New Zealand, Norway, Switzerland, the Netherlands, UK, and USA) participated in the first survey, and 28 expert centres from 12 different countries participated in the second (Austria, Australia, Argentina, Belgium, Chile, France, Ireland, Mexico, New Zealand, the Netherlands, UK, and USA). The number of respondents varied for each individual question.

Frequency of breastfeeding during KDT

Almost half of the centres (16 out of 36) reported having access to a specialized human milk nurse on their team, nearly two-thirds of respondents (20 out of 36) estimated that the proportion of infants using human milk during KDT treatment was lower than the average breastfeeding rate in their country, on the basis of personal experience, while one-third

(11 out of 36) estimated that it was similar and two considered it higher (2 out of 36).

PRACTICAL RECOMMENDATIONS FOR THE USE OF HUMAN MILK DURING KDT IN INFANTS

In this section, for each item the results from the literature review and the surveys are followed by a summary and recommendations for clinical practice.

Patient selection: patient characteristics

Literature

The indications for KDT in infants have been detailed in previously published guidelines as well as a consensus paper^{8,9} and have remained unchanged over the past decade. KDT remains the sole causative treatment for GLUT1 deficiency syndrome and pyruvate dehydrogenase complex deficiency. The reported application of KDT for drug-resistant epilepsy in infants is mainly in the treatment of infantile epileptic spasm syndrome,^{8,9} although this is rapidly expanding to include infants with other developmental and epileptic encephalopathies. There are few reports of newborn babies and very young infants^{7,32–34} and, so far, these reports are consistent with effective and safe use; however, no new evidence has emerged. As previously stated in other guidelines, before initiating KDT, children should be screened for conditions for which KDT is contraindicated.^{8,9}

Survey

Across all centres, a median of 17 children (range 1–50) older than 12 months and a median of four infants (range 0–20) younger than 12 months started KDT per year. Across 18 centres, a median of one neonate (range 0–6) started KDT, eight centres started from birth, three centres at 2 weeks, and seven centres at 4 weeks. The second survey ($n=28$, 2023) showed that four centres started KDT in one to six newborn infants per year. The main reason given for not choosing KDT was the lack of transfer/opportunity.

Reasons for not introducing KDT in neonates are listed in Table 1. Table 2 shows aetiologies/indications for KDT in newborn babies and infants younger and older than 3 months.

Summary

The results of the surveys, which largely reflect previous KDT guidelines^{8,9} and our current literature review, indicate infrequent use in neonates owing to lack of indication or opportunity, as neonates are often cared for in other hospitals or referred to other hospitals for epilepsy management beyond the neonatal period.

Both surveys report the use of KDT in infants in well-established indications. GLUT1 deficiency syndrome and

pyruvate dehydrogenase complex deficiency remain important conditions where KDT is currently the only treatment to deliver adequate energy to the brain.

Recommendations

A comprehensive evaluation should be performed when considering KDT, particularly in newborn babies and early infancy. Age-related epilepsy syndromes³⁵ are mainly determined by aetiology, so specific treatments may be particularly effective, such as certain antiseizure medications for genetic channelopathies (e.g. sodium channel blockers for

TABLE 1 Reasons for not starting ketogenic diet therapy in neonates.

Reason	Number of respondents, <i>n</i> = 36 (2021)
Never had cases with such indications/ neonatal patients are taken care of in another area of the hospital	18
Not often thought/unaware that ketogenic diet therapy in neonates is a possibility	2
Lack of indications for the neurologist	2
First attempts with other antiseizure medication	2
Usually need to perform genetic tests/ other investigations and see whether medication alone helps	1
Risk of hypoglycaemia, difficulties of management with breastfeeding	1
Missing case numbers	1

TABLE 2 Indications for ketogenic diet therapy in infants and neonates.

In general (<i>n</i> = 36) (2021)	
Epilepsy syndrome/aetiology	Respondents
Epilepsy ^a before 3 months of age	24
Epilepsy ^a between 3 and 12 months of age	33
PDHc or GLUT1 deficiency before 3 months of age	30
PDHc or GLUT1 deficiency after 3 months of age	32
Before 3 months of age (<i>n</i> = 32)	
Epilepsy ^a	25
GLUT1 deficiency	7
PDHc deficiency	4
Refractory status epilepticus	1
After 3 months of age (<i>n</i> = 35)	
Epilepsy ^a	34
GLUT1 deficiency	5
PDHc deficiency	4
Febrile infection-related epilepsy syndrome	1

Abbreviations: GLUT1, glucose transporter type 1; PDHc, pyruvate dehydrogenase complex.

^aEpilepsy^a includes the following answers: epilepsy, generalized seizures, Dravet syndrome, Ohtahara syndrome, refractory epilepsy, infantile spasms/West syndrome, refractory epileptic encephalopathy.

KCNQ2 or for SCN8A developmental and epileptic encephalopathy). As reported in the past, KDT can be used in infants with a good balance of benefits and risks. The use of human milk or breastfeeding does not change the clinical indications or contraindications for the use of KDT.

Preparing/motivating the mother

The mother's motivation and desire are fundamental to the continuation of human milk or breastfeeding during KDT. However, even the decision of early breastfeeding depends on the time, resources, and support of healthcare professionals for breastfeeding counselling.³⁶ Experts must therefore emphasize very clearly that weaning from human milk/breastfeeding is not required when initiating KDT. Pro and contra of using expressed human milk mixed with KDT formula or of using KDT formula followed by natural breastfeeding are listed in Figure 1, along with practical recommendations in Figure 2. This should be discussed with the mother before initiation of KDT.

Maternal diet and supplements

It is not common practice to advise the mother to follow a modified Atkins diet or any other type of carbohydrate-restricted diet to achieve ketosis in breastfed infants. However, healthy eating patterns and supplements are generally recommended during breastfeeding to meet increased needs.³⁷

Literature

To date, only one case report has described the effectiveness of maternal KDT in controlling seizures in breastfed infants, along with analysis of the nutritional composition of the maternal human milk³⁰ and description of maternal diet regimen³¹ (Table S1). However, several publications have reported life-threatening adverse events due to severe ketoacidosis when mothers started KDT as a weight loss lifestyle while breastfeeding.^{38–44} In these studies, maternal dietary regimens were not well described. The authors therefore urgently warn against a carbohydrate-reduced diet during breastfeeding.

Survey

In 2021, only 2 out of 36 experts recommended maternal dietary changes, either a carbohydrate-restricted diet or low glycaemic index treatment; this result was repeated in the survey in 2023 (2 out of 28).

Summary

Well-documented information on the safety and effectiveness of maternal KDT while breastfeeding, for both infant seizure control and maternal dietary composition, is scarce. Maternal KDT has yet to be studied in detail. An example of a safe way to introduce KDT in breastfeeding mothers could be the 'low and slow' method of Fabre and Ronen.³¹ Future studies are required and should include analysis of human milk.




FIGURE 1 Pros and contras of human milk use during ketogenic diet therapy.




FIGURE 2 How to do it: the process of incorporating human milk into ketogenic diet therapy.

Recommendations

Maternal dietary changes should not be initiated without medical and dietary advice from a team of experts who are aware of the potential adverse events. This should only be

done in a gradual and controlled manner if the infant is not seizure free on KDT combined with human milk.

Dietary composition

Ketogenic diet composition in infants

The international guideline published in 2016 provides recommendations for the optimal management of KDT in infants (Table S2).⁸ The use of human milk or breastfeeding during KDT does not change the guidelines for infants.

Ketogenic diet composition in infants using human milk

There are two possible methods for KDT calculation: using diet composition based on human milk analysis or using average human milk composition (Table S3).

Literature

There is a lack of literature on the analysis of human milk in the context of KDT, and detailed information on nutritional data is sparse, as human milk depends on various factors such as maternal eating habits⁴⁵ and infant age.^{46,47} Only one case report³⁰ systematically analysed human milk (Table S1). Two studies used average macronutrient reference values of human milk,^{16,28} and one described this as moderately reducing the KDT ratio (range 2.1–2.5),¹⁶ which may also be true when human milk was not calculated in the prescription.^{27,29} When breastfeeding was included ($n=5$),¹⁶ human milk volume was calculated by initial weighing before and after breastfeeding and/or counting time (minutes) per breast side. Ketosis was measured 1 hour after breastfeeding.

Survey

Nutritional composition of human milk. In 2021, only one centre analysed the macronutrient composition of human milk; centres on the whole instead assumed average values for human milk using multiple reference values (e.g. Souci and Fachmann, Food and Agriculture Organization of the United Nations/World Health Organization, Ketocalculator, McCance and Widdowson, NEVO, Milkbank). Only one centre reported analysing human milk macronutrient composition, when difficulties were encountered (achieving ketosis, problems with growth, or inadequate seizure control).

Ketogenic diet ratio at start and during maintenance. In 2021 ($n = 36$), half of all centres started KDT in infants with a ratio of 1:1 to 2:1, 10 used a ratio between 2:1 and 3:1, and only three started with a ratio of 3:1 to 4:1. However, 22 centres did start with a lower KDT ratio than that previously stated in the questionnaire. In neonates, KDT ratios were usually lower at baseline: nine centres started with a 1:1 to 2:1 ratio, only three with a 3:1 to 4:1 ratio, and only one centre started with a 4:1 ratio. Nine centres also started with the previously stated ratio.

During maintenance, four centres reported using ratios between 3:1 and 4:1, while three used lower ratios on an individual basis (lowest possible ratio to achieve adequate levels of ketosis).

In 2023 ($n = 28$), ratios adopted in infants were even lower: 12 of the respondents reported ratios from 1:1 to 2:1, while another 12 used ratios of 2:1 to 3:1. Only one centre reported an individual approach according to the specific infant. This was also true for KDT use in neonates in 2023, as four centres used KDT ratios ranging from 1:1 to 2:1, two centres used ratios ranging from 2:1 to 3:1, and only one centre reported a ratio between 3:1 and 4:1.

Summary

Detailed information on nutrient composition while using human milk during KDT is scarce owing to limited data on human milk analysis and difficulties in measuring human milk volume when breastfeeding is supported. Average reference values from different sources are mainly used for expressed human milk. Current guidelines for infants recommend KDT ratios up to 3:1. In our surveys from 2021 and 2023, a trend towards lower ratios has been observed for infants and neonates. In the literature, only one study¹⁶ reported that KDT including human milk with modified ratios (below 3:1) is equally effective and safe while ensuring age-appropriate protein intake for growth.

Recommendations

(1) For diet calculation, the recommendations from the infant guidelines should be used. (2) A moderate KDT ratio ranging from 2:1 to 3:1 is recommended to allow adequate protein intake for growth and to facilitate use of human milk and breastfeeding. Lower or higher ratios can be used on an individual basis. (3) Standardized values for expressed

human milk should be used for nutritional calculations (see, for example, Gidrewicz and Fenton;⁴⁶ Lawrence et al.;⁴⁸ Jenness;⁴⁹ Ballard and Morrow;⁵⁰ Wu et al.⁵¹). (4) A nutritional analysis of human milk is recommended when insufficient ketosis, seizure reduction, or growth occurs to add nutritional supplements and improve KDT individually.

Using human milk during KDT

Advantages of using human milk

Literature

Exclusive breastfeeding is recommended for infants for the first 6 months after birth^{21–23} by the American Academy of Pediatrics and the World Health Organization, as is the introduction of complementary foods along with breastfeeding for infants from 6 months to 2 years and beyond.

Breastfeeding carries unique physiological benefits for both the infant and the breastfeeding mother.^{52–55} Besides promoting optimal growth and development,⁵⁵ breastfeeding has prospectively been linked to higher scores on neurological and cognitive tests later in life.^{56–59} Moreover, breastfeeding seems to reduce the risk for childhood epilepsy,⁶⁰ to prevent infectious diseases, and limit the onset of some chronic diseases such as diabetes and obesity^{53,54} (Table 3).

Survey

Table 4 shows the survey (2021) data ranking the benefits of using human milk during KDT. The highest scores were obtained for fulfilling mother's wishes and for bonding with the mother over any other medical reason.

Profile of human milk in KDT

Studies have shown differences in the composition of human milk at the beginning (2–3 minutes, foremilk) and the end of breastfeeding (hindmilk).^{61,62} Hindmilk contains a higher concentration of fat, energy, and vitamins,^{61,63,64} but different lipid profiles of foremilk and hindmilk have only recently been studied.⁶⁵ Liquid chromatography–tandem mass spectrometry has shown that the fat concentration in hindmilk was almost twice that in foremilk ($120.6 \pm 66.7 \mu\text{mol/mL}$ vs $68.6 \pm 33.3 \mu\text{mol/mL}$). Analyses indicated that the lipid profile of human milk also reflected individual characteristics of the mother. However, data on the use of different parts of human milk during KDT treatment are not available and reference values include average data, hence including both foremilk and hindmilk.

Survey

Twenty-seven centres used both hindmilk and foremilk, while two used only hindmilk and one only foremilk.

The only centre analysing human milk composition did this only when experiencing difficulties, not routinely. Sixteen respondents did not add any supplements to improve

TABLE 3 Benefits of breastfeeding for both the infant and the mother.

Reduced risks for the infant	Reduced risks for the mother
Gastro-intestinal tract infection	Immediate benefits after birth (e.g. reduced bleeding, postpartum weight loss reduce stress)
Respiratory infection, asthma, hospitalization for respiratory infection	Type 2 diabetes
Otitis media	Cardiovascular risk
Cognitive development	Breast cancer risk
Sudden infant death syndrome	Ovarian cancer risk
Acute lymphoblastic leukaemia	Visceral adiposity
Obesity	
Epilepsy in childhood	

TABLE 4 The main benefits of using human milk during KDT and their ranking ($n = 36$).

Advantage	Ranking ^a
Mother's wish	1
Bonding with the mother	2
Fewer infections	2
Helpful for coping with episodes of intercurrent illness	4–5
Less constipation	5–7
Adequate ketosis despite lower KDT ratio and more carbohydrates allowed	6–8
Fewer adverse effects during initiation	7
If KDT is not effective, breastfeeding can be continued	3 and 8

Abbreviation: KDT, ketogenic diet therapy.

^a1, most important; 8, least important.

the composition of human milk. Eight respondents added maternal vitamins, breastfeeding supplements, ketogenic formula, vitamin D, or human milk fortifiers. Eleven centres did not respond to this question.

Twenty-two centres had access to a (national) human milk bank, but only six used human milk from a human milk bank in case of shortages.

Recommendations

Currently there is no clear evidence of a clinical advantage using hindmilk rather than foremilk, although differences in lipid composition might suggest a theoretical advantage for hindmilk. This topic needs further research.

Application of human milk: different strategies of clinical practice

Motzfeld et al.¹⁷ were the first to use human milk in infants with inborn errors of metabolism. They successfully

developed a strategy whereby children diagnosed with phenylketonuria (those with phenylalanine blood levels below 1200 $\mu\text{mol/L}$) were breastfed at every meal after drinking a large amount of protein-free formula. This was based on the idea that, depending on the volume of the bottle, infants adjust the amount of human milk they drink: the more volume in the bottle, the less human milk is ingested. This strategy of using human milk in infants with inborn errors of metabolism has proved to be very convenient. Adjustments based on laboratory values can be easily made by adjusting the bottle volume. In addition, it promotes the bond between mother and child, as breastfeeding continues. This strategy was replicated in the guidelines for phenylketonuria and for other inborn errors of metabolism,^{18,19} but has not been widely implemented in KDT practice.

Literature

As described in the literature review (Table S1), different strategies of administering human milk have been reported.^{16,27–29} These included (1) mixing expressed human milk with ketogenic formula;^{28,29} (2a) bottle-feeding ketogenic formula before breastfeeding ($n = 5$),¹⁶ ($n = 1$);²⁷ (2b) alternating ketogenic formula both three to four times daily with breastfeeding, beginning with breastfeeding followed by ketogenic formula ($n = 2$).²⁷

Survey

Nineteen centres included human milk into KDT only for infants, 11 centres included human milk both for infants and for newborn babies, and five did not include human milk in either age group.

Eighteen centres initiated KDT when infants and newborn babies were breastfed, while 11 did so only for infants. Six centres did not initiate KDT during breastfeeding. Mixed strategies were reported for including human milk into KDT. The two most reported practices were (1) calculating the amount of expressed human milk and bottle-feeding it along with ketogenic formula, and (2) bottle-feeding ketogenic formula followed by breastfeeding. The percentage of human milk contained in KDT varied widely and was usually unmeasured or customized on an individual basis by most respondents. Table 5 shows the different strategies of using human milk.

Calculated amount of expressed human milk at every meal. The calculated volume of expressed human milk per day was 5% to 10% ($n = 5$), 10% to 25% ($n = 8$), 30% to 50% ($n = 3$), or was calculated individually ($n = 6$).

Calculated amount of KDT formula followed by breastfeeding. The estimations of the volume of human milk consumed varied greatly among respondents. One-third had the volume measured on the basis of individual circumstances ($n = 10$), or by time spent at the breast and measured post-meal ketosis ($n = 8$), while another third did not measure volume at all ($n = 9$) or did not apply any of the

suggested measurements ($n=8$). Some respondents weighed the infant before and after breastfeeding ($n=4$) and allowed one or two separate full breastfeeds per day alongside bottles of ketogenic formula ($n=1$).

Some respondents reported that allowing breastfeeding was motivated by adequate levels of ketosis, infants' ages, mothers' preferences and abilities, and by the individual's level of seizure control (e.g. if seizure control was good without measuring human milk, no additional steps appeared necessary; however, in case of poor ketosis or seizure control, accuracy needed improvement). Most often, the first ketogenic meal was started with a ketogenic bottle, and then breastfeeding was allowed overnight, albeit with limited feeding time.

However, other respondents did not use breastfeeding inclusion strategies, because most preferred expressed human milk mixed with ketogenic formula, or only expressed hindmilk, or stopped breastfeeding altogether when infants started KDT.

The second survey ($n=28$, 2023) showed that current practice is on average the same as in 2021: calculated expressed milk mixed with KDT formula ($n=18$), calculated amount of KDT formula followed by breastfeeding ($n=6$), and eight centres did not respond.

Summary

In the literature, the strategy of bottle-feeding ketogenic formula at first followed by breastfeeding was undertaken only in six reported cases out of eight where breastfeeding was included;^{16,27} all other infants received ketogenic formula mixed with a calculated amount of expressed human milk. According to our survey, both strategies are applied with similar frequency in clinical practice. Strategies to improve accuracy included limiting breastfeeding time and weighing the infant before and after breastfeeding. However, most measured no volume at all, particularly when ketosis was adequate and seizure control good.

The reported range of 5% to 50% daily volume as expressed human milk was consistent with the results of our survey, as half of the respondents ($n=13$) were using 5% to 25% of daily volume as expressed human milk.

Recommendations

The strategy of choice on how to use human milk as part of KDT is dependent on several factors: availability of human

TABLE 5 Strategies of using human milk during KDT ($n=36$).

Method	Respondents
Calculated amount of expressed human milk mixed with KDT formula at every meal	23
Calculated amount of KDT formula (standard solution) followed by breastfeeding	22
Calculated amount of KDT formula (standard solution) after breastfeeding	3

Abbreviation: KDT, ketogenic diet therapy.

milk, mothers' desires to express or breastfeed, the infant's health status, and their ability to be breastfed.

Ideally, ketogenic formula should be given by bottle in the first instance, followed by breastfeeding. With this method, both the infant and the mother would benefit from breastfeeding.

The level of accuracy should depend on the level of seizure control: in case of poor seizure control, feeding problems, or insufficient ketosis, using expressed human milk instead of breastfeeding is recommended.

Monitoring

Adverse events

KDT is associated with the risk of adverse events. As with any KDT, dietary and medical monitoring is required. Gastro-intestinal side effects are the most common, usually transient, and controlled with diet modification without the need to stop KDT. These have been described in the current guidelines;^{8,9} however, new studies have emerged. In summary, early adverse effects in infants under 2 years were most commonly hypoglycaemia and vomiting, while after 1 month of KDT metabolic acidosis, vomiting, and constipation were more frequent,⁶⁶ with acute adverse effects occurring more frequently in infants under 1 year. In the past, a higher risk of lethargy and kidney stones was observed when children were younger,⁶⁷ and hypercalciuria independently increases the risk of developing kidney stones.⁶⁸ Up to 7% of children develop kidney stones while on KDT (uric acid, calcium oxalate, calcium phosphate, or mixed stones).^{68,69} The risk further increased with long-term treatment^{66,70} and concomitant use of carbonic anhydrase inhibitors owing to metabolic acidosis.⁷¹

There is no evidence suggesting that using human milk prevents or aggravates such risks.

Survey

Twenty-six centres targeted a specific level of ketosis, with 18 targeting a ketone range between 2 and 3 mmol/L, eight targeting a ketone level between 3 and 4 mmol/L, and only one centre targeting 4 mmol/L or more. Four centres did not target a specific level of ketosis at all.

Low ketone levels (<1.5 mmol/L) were responsible for the KDT modification in 27 of the respondents, as was high ketosis (>5 mmol/L) in 23. Intermediate illnesses were a reason for 12 to modify the diet.

Recommendations

Clinical examinations and monitoring during KDT should be performed as suggested in the infant guidelines for KDT:⁸ that is, a dietician and a physician experienced in KDT management should closely monitor and manage the infant.

Challenges of using human milk in KDT in infants

Literature

Reports of challenges while using human milk or breastfeeding during KDT are limited, but maternal discomfort (mother bitten by the infant, pain when expressing human milk) were common reasons why mothers chose to stop using human milk or breastfeeding.²⁷ In the past, mothers were often told to stop breastfeeding before starting KDT with their child,²⁸ thereby depriving the mother of choice.³⁶ However, to date, systematic data on challenges for human milk inclusion and breastfeeding during KDT are lacking.

Survey

Respondents reported that the main challenges of using human milk in KDT were low ketosis ($n = 27$), high ketosis ($n = 23$), reduced production of human milk ($n = 20$), severe clinical condition of the infant ($n = 15$), food refusal/low fluid intake ($n = 14$), intercurrent illness ($n = 12$), frequently low ketosis ($n = 10$), ineffective suckling ($n = 10$), inexperienced mother ($n = 6$), and frequently high ketosis ($n = 3$).

Summary

Two main issues limited the use of human milk in KDT. First, there were infant-related issues that were relatively common: fluctuations in ketosis, poor infant health, food refusal, and intermittent illness. Second, there were issues related to the mother that are common issues in any mother–infant dyad owing to stress: low milk production, little breastfeeding experience, and ineffective suckling.

Recommendations

Clinical examinations should be performed as suggested in the infant guidelines for KDT.⁸ Nurses specialized in breastfeeding should provide support and advice on the practical aspects of breastfeeding.

Assessment of response to KDT: seizure- and non-seizure-related outcomes

The infant guidelines recommend that the evaluation period for KDT^{8,9} is at least 2 to 3 months and the diet should be continued during this period. Earlier evaluation is necessary though for infantile epileptic spasms syndrome where KDT is recommended as second- or third-line treatment.^{8,9,72} The goal in infantile epileptic spasms syndrome is seizure freedom. An assessment of response to KDT should be evaluated after 4 weeks because psychomotor development is crucial at this age^{72,73} and changes in medication may be required alongside KDT.

Non-seizure-related outcomes have to be included which measure improvements in cognition, alertness, attention,

and behaviour; these are mostly reported subjectively rather than systematically owing to the lack of standardized cognitive and quality of life outcomes.^{74,75}

Literature on human milk in KDT and assessment of response

Effectiveness of KDT treatment on seizures in infants using KDT with human milk is described in detail in the literature review (Table 1),^{16,27–29} and ranged from 33% to 53% for seizure freedom, and from 67% to 80% for a reduction in seizures of more than 50%. This is consistent with the effectiveness reported in the literature in this age group without using human milk, where a seizure reduction of more than 50% occurs in an average of 60% of infants, and seizure freedom in about 30%.^{2,4,6,7,11}

Non-seizure-related outcomes were only reported in the study by Le Pichon et al.,²⁹ which showed an improvement in quality of life in 89% of infants using a parental report with yes/no questions on alertness, interactions, and performance in school.

Survey

The main reported outcome measures were seizure reduction ($n = 27$), improvement of motor symptoms/dystonia in GLUT1 deficiency ($n = 26$), seizure freedom ($n = 21$), and others ($n = 5$); improved well-being, improved development, attention and perception, improving intestinal flora, and not specified.

Recommendations

Seizure-related outcomes remain the focus for outcome assessment in KDT. A core outcome set of domains for KDT in childhood epilepsy including non-seizure-related outcomes was recently developed by consensus involving parents and health-care professionals.⁷² Further development of this work will enable its implementation both in research and in clinical settings to standardize non-seizure-related outcome measures, although this is difficult for infants in the first year of life.

REASONS FOR DISCONTINUATION

Reasons for discontinuing human milk use in KDT

Literature

Reports in the literature on reasons for discontinuing human milk/breastfeeding are limited. Factors related to the infant were increased lactate,²⁷ increasing age,^{28,29} and decreased interest.²⁹ Maternal factors included discomfort²⁷ and loss of milk production.²⁹

Survey

The most important reasons for discontinuing human milk in KDT were shortage of human milk ($n = 22$), inadequate ketosis ($n = 14$), and severely compromised infant health ($n = 13$). Other reasons reported were severe adverse events ($n = 6$) and maternal inexperience of breastfeeding ($n = 4$).

Reasons for discontinuing KDT

The infant guidelines⁸ addressed this issue and suggested trying to discontinue KDT once children have been monitored for at least 2 years. However, given the typical age-related nature of infantile epileptic spasms syndrome, one randomized controlled trial has reported a shorter use in this syndrome.⁷⁶ Conversely, those with GLUT1 and pyruvate dehydrogenase complex deficiencies benefit from continuing KDT, in some form, indefinitely. No recent data support changing this recommendation.

Recommendations

Apart from difficulties maintaining breastfeeding or obtaining expressed human milk, discontinuation of KDT should follow previously published recommendations.

The mother's desire to use human milk should be at the heart of the decision to continue or discontinue breastfeeding. In case of human milk shortage, consider using milk from a human donor.

CONCLUSION AND FUTURE RESEARCH

The use of human milk and breastfeeding in KDT for infants and newborn babies is limited in daily practice, which

has not changed in recent years. By reviewing the literature and using data about current practice collected by two international surveys (2021 and 2023), we present our collective advice about the inclusion of human milk in KDT in [Table 6](#).

Barriers to the inclusion of human milk and breastfeeding in KDT have only been partly overcome in KDT compared with phenylketonuria or other inborn errors of metabolism. In clinical practice there is a lack of referrals and therefore opportunities to implement this approach, especially in newborn babies. Even experienced KDT practitioners often prefer to include expressed human milk instead of including breastfeeding, to accurately calculate the dietary components. As the surveys have shown, there are many ways to include human milk in KDT. It remains unclear whether the way human milk is included in KDT results in any change in the effectiveness on seizure reduction, time to reach ketosis, or occurrence of adverse events. The inclusion of lactation consultants could increase the success of including human milk and breastfeeding in the feeding regimens of infants on KDT. A supplemental nursing system is a tool that could be used to simultaneously provide both human milk and ketogenic formula to an infant while breastfeeding. A small tube next to the mammilla delivers formula as the infant sucks, which could allow more precise control of formula volume. With the supplemental nursing system, foremilk can be discarded or medium-chain triglycerides can be used instead of KDT formula for infants with intolerance and is certainly worthy of further exploration.⁷⁷

However, there is also a need to encourage and further investigate not only the use of human milk during KDT but also breastfeeding with all its physiological benefits. Increased knowledge of the nutritional aspects of human milk, either through analysis of human milk or by using specific parts of human milk (hindmilk), can help to develop more precise strategies for the inclusion of human milk and breastfeeding during KDT. The use of human milk does not

TABLE 6 Overview of recommendations.

Recommendations	
1	Human milk can be implemented in KDT which does not change indications or contraindications of KDT in infants.
2	Ideally, ketogenic formula should be given by bottle first, followed by breastfeeding. With this method, both the infant and the mother would benefit from breastfeeding.
3	Use expressed milk in case of poor seizure control, insufficient ketosis, poor growth, and feeding difficulties.
4	The amount of expressed milk ranges from 5% to 50% depending on ketosis and seizure control. Mothers should be stimulated to continue pumping and store expressed milk for maintenance of KDT.
5	In theory, hindmilk would be preferred.
6	Use standardized values of human milk for diet calculation.
7	Nutritional composition of the KDT is calculated according to recommendations from infant guidelines.
8	Moderate KDT ratio ranging from 2.0:1 to 2.5:1 for adequate protein intake.
9	Analyse human milk composition when there is insufficient ketosis, seizure reduction, or growth issues.
10	Maternal diet may only be adapted by an expert team while monitored closely and in case of poor seizure control in a breastfed child.
11	Ketone levels, monitoring, evaluation of effectiveness, and discontinuation according to the 2016 infant guidelines.
12	Consult a lactation nurse to support mothers.

Abbreviation: KDT, ketogenic diet therapy.

change either knowledge or previously published guidelines for the use of KDT in infants but rather complements them for the benefit of mother and child.

Non-seizure-related outcomes that have not been systematically studied in KDT so far need to be implemented in future research, and specifically tailored to infants. Prospective real-world registries would be the ideal way to gather further information and guide practice in terms of KDT at all ages.

ACKNOWLEDGEMENTS

We thank all centres that have contributed by responding to the questionnaires. We also thank Stéphanie Voogd for her testimonial (Appendix S3), and Anika Maass and Francesca Sutter for reviewing the pocket guide. A pocket guide for clinicians was developed and design was supported by Nutricia (Appendix S4).

CONFLICT OF INTEREST STATEMENT

The authors have stated that they had no interests that might be perceived as posing a conflict or bias.

DATA AVAILABILITY STATEMENT

There is no data available.

ORCID

Elles van der Louw  <https://orcid.org/0000-0003-3245-0471>

J. Helen Cross  <https://orcid.org/0000-0001-7345-4829>

Stéphanie Auvin  <https://orcid.org/0000-0003-3874-9749>

Anastasia Dressler  <https://orcid.org/0000-0002-1518-8646>

REFERENCES

- Nordli DR, Jr, Kuroda MM, Carroll J, Koenigsberger DY, Hirsch LJ, Bruner HJ, Seidel WT, De Vivo DC. Experience with the ketogenic diet in infants. *Pediatrics* 2001; 108: 129–33.
- Kossoff EH, Pyzik PL, McGrogan JR, Vining EP, Freeman JM. Efficacy of the ketogenic diet for infantile spasms. *Pediatrics* 2002; 109: 780–3.
- Klepper J, Leindecker B, Bredahl R, Athanassopoulos S, Heinen F, Gertsen E, Florcken A, Metz A, Voit T. Introduction of a ketogenic diet in young infants. *Journal of inherited metabolic disease* 2002; 25: 449–60.
- Kossoff EH, McGrogan JR, Freeman JM. Benefits of an all-liquid ketogenic diet. *Epilepsia* 2004; 45: 1163.
- Kang HC, Kim HD, Kim DW. Short-term trial of a liquid ketogenic milk to infants with West syndrome. *Brain & development* 2006; 28: 67.
- Hong AM, Turner Z, Hamdy RF, Kossoff EH. Infantile spasms treated with the ketogenic diet: prospective single-center experience in 104 consecutive infants. *Epilepsia* 2010; 51: 1403–7.
- Dressler A, Trimmel-Schwahofer P, Reithofer E, Groppe G, Muhlechner A, Samuelli S, Grabner V, Abraham K, Benninger F, Feucht M. The ketogenic diet in infants—Advantages of early use. *Epilepsy research* 2015; 116: 53–8.
- van der Louw E, van den Hurk D, Neal E, Leindecker B, Fitzsimmon G, Dority L, Thompson L, Marchio M, Dudzinska M, Dressler A, Klepper J, Auvin S, Cross JH. Ketogenic diet guidelines for infants with refractory epilepsy. *European journal of paediatric neurology: EJPEN: official journal of the European Paediatric Neurology Society* 2016; 20: 798–809.
- Kossoff EH, Zupec-Kania BA, Auvin S, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, Buchhalter JR, Caraballo RH, Cross JH, Dahlin MG, Donner EJ, Guzel O, Jehle RS, Klepper J, Kang HC, Lambrechts DA, Liu YMC, Nathan JK, Nordli DR, Jr, Pfeifer HH, Rho JM, Scheffer IE, Sharma S, Stafstrom CE, Thiele EA, Turner Z, Vaccarezza MM, van der Louw E, Veggiotti P, Wheless JW, Wirrell EC, Charlie F, Matthew's F, Practice Committee of the Child Neurology S. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. *Epilepsia open* 2018; 3: 175–92.
- Dressler A, Benninger F, Trimmel-Schwahofer P, Groppe G, Porsche B, Abraham K, Muhlechner A, Samuelli S, Male C, Feucht M. Efficacy and tolerability of the ketogenic diet versus high-dose adrenocorticotropic hormone for infantile spasms: A single-center parallel-cohort randomized controlled trial. *Epilepsia* 2019; 60: 441–51.
- Kim SH, Shaw A, Blackford R, Lowman W, Laux LC, Millichap JJ, Nordli DR, Jr. The ketogenic diet in children 3 years of age or younger: a 10-year single-center experience. *Scientific reports* 2019; 9: 8736.
- Titre-Johnson S, Schoeler N, Eltze C, Williams R, Vezyroglou K, McCullagh H, Freemantle N, Heales S, Kneen R, Marston L, Martland T, Nazareth I, Neal E, Lux A, Parker A, Agrawal S, Fallon P, Cross JH. Ketogenic diet in the treatment of epilepsy in children under the age of 2 years: study protocol for a randomised controlled trial. *Trials* 2017; 18: 195.
- Schoeler N, Lyons L, Jain R, Marston L, Freemantle N, Cross HJ. Oral Presentations: Ketogenic Diet in Infants with Epilepsy (KIWE): A Randomised Controlled Trial. *Developmental medicine and child neurology* 2023; 65: 5–17.
- Kossoff EH, Zupec-Kania BA, Amark PE, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, Buchhalter JR, Caraballo RH, Helen Cross J, Dahlin MG, Donner EJ, Klepper J, Jehle RS, Kim HD, Christiana Liu YM, Nation J, Nordli DR, Jr, Pfeifer HH, Rho JM, Stafstrom CE, Thiele EA, Turner Z, Wirrell EC, Wheless JW, Veggiotti P, Vining EP, Charlie Foundation PCotCNS, Practice Committee of the Child Neurology S, International Ketogenic Diet Study G. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. *Epilepsia* 2009; 50: 304–17.
- Martin-McGill KJ, Jackson CF, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. *The Cochrane database of systematic reviews* 2018; 11: CD001903.
- Dressler A, Hafele C, Giordano V, Benninger F, Trimmel-Schwahofer P, Groppe G, Samuelli S, Feucht M, Male C, Repa A. The Ketogenic Diet Including Breast Milk for Treatment of Infants with Severe Childhood Epilepsy: Feasibility, Safety, and Effectiveness. *Breastfeeding medicine: the official journal of the Academy of Breastfeeding Medicine* 2020; 15: 72–8.
- Motzfeldt K, Lilje R, Nylander G. Breastfeeding in phenylketonuria. *Acta paediatrica* 1999; 88: 25–7.
- Banta-Wright SA, Press N, Knafl KA, Steiner RD, Houck GM. Breastfeeding infants with phenylketonuria in the United States and Canada. *Breastfeeding medicine: the official journal of the Academy of Breastfeeding Medicine* 2014; 9: 142–8.
- Pichler K, Michel M, Zlamy M, Scholl-Buergi S, Ralsler E, Jorg-Streller M, Karall D. Breast milk feeding in infants with inherited metabolic disorders other than phenylketonuria - a 10-year single-center experience. *Journal of perinatal medicine* 2017; 45: 375–82.
- Gartner LM, Morton J, Lawrence RA, Naylor AJ, O'Hare D, Schanler RJ, Eidelman AI, American Academy of Pediatrics Section on B. Breastfeeding and the use of human milk. *Pediatrics* 2005; 115: 496–506.
- Meek JY, Noble L. Technical Report: Breastfeeding and the Use of Human Milk. *Pediatrics* 2022; 150.
- Meek JY, Noble L, Section on B. Policy Statement: Breastfeeding and the Use of Human Milk. *Pediatrics* 2022; 150.
- Butte NF, Lopez-Alarcon MG, Garza C, Expert Consultation on the Optimal Duration of Exclusive B. Nutrient adequacy of exclusive

- breastfeeding for the term infant during the first six months of life / Nancy F. Butte, Mardia G. Lopez-Alarcon, Cutberto Garza. Geneva: World Health Organization; 2002.
24. WHO. Ten steps to successful breastfeeding (accessed 13.11.2023)
 25. van der Louw E, Aldaz V, Harvey J, Roan M, van den Hurk D, Cross JH, Auvin S, Review G. Optimal clinical management of children receiving ketogenic parenteral nutrition: a clinical practice guide. *Developmental medicine and child neurology* 2020; 62: 48–56.
 26. McGrath JM, Brandon D. Why Human Milk and Not Breast Milk Among Other Changes: 2018 Author Guideline Updates. *Advances in neonatal care: official journal of the National Association of Neonatal Nurses* 2017; 17: 325–6.
 27. Cole NW, Pfeifer HH, Thiele EA. Initiating and Maintaining the Ketogenic Diet in Breastfed Infants. *ICAN: Infant, Child, & Adolescent Nutrition* 2010; 2: 177–80.
 28. Fenton C, Randall R, Groveman SA, Chee CM, Bergqvist AGC. Use of Expressed Breast Milk With the Ketogenic Diet. *ICAN: Infant, Child, & Adolescent Nutrition* 2015; 7: 342–6.
 29. Le Pichon JB, Thompson L, Gustafson M, Abdelmoity A. Initiating the ketogenic diet in infants with treatment refractory epilepsy while maintaining a breast milk diet. *Seizure* 2019; 69: 41–3.
 30. Tan-Smith C, Little H, Fabe J, Dickson C, Shillito P. Increase of Human Milk Fat Inducing Nutritional Ketosis in Exclusively Breastfed Infant, Brought About by Treating the Mother With Ketogenic Dietary Therapy. *Journal of human lactation: official journal of International Lactation Consultant Association* 2022; 38: 281–6.
 31. Fabe J, Ronen G. Canadian Nutrition Society: Scientific Abstracts from the 9th Annual Scientific Meeting / Société canadienne de nutrition: Résumés scientifiques de la 9e réunion scientifique annuelle Ketogenic diet therapy for epilepsy: low ratio slow initiation in a Canadian outpatient setting – achieving optimal diet prescription for seizure control – 1 year follow up. *Applied Physiology, Nutrition, and Metabolism* 2018; 43: S1-S42.
 32. Phitsanuwoong C, Kim JA, Schimpf S, Nordli DR, Jr. Experience with the ketogenic diet in premature neonates. *Epilepsia open* 2023; 8: 200–4.
 33. Thompson L, Fecske E, Salim M, Hall A. Use of the ketogenic diet in the neonatal intensive care unit-Safety and tolerability. *Epilepsia* 2017; 58: e36-e9.
 34. Goyens P, De Laet C, Ranguelov N, Ferreiro C, Robert M, Dan B. Pitfalls of ketogenic diet in a neonate. *Pediatrics* 2002; 109: 1185–6; author reply -6.
 35. Zuberi SM, Wirrell E, Yozawitz E, Wilmshurst JM, Specchio N, Riney K, Pressler R, Auvin S, Samia P, Hirsch E, Galicchio S, Triki C, Snead OC, Wiebe S, Cross JH, Tinuper P, Scheffer IE, Perucca E, Moshe SL, Nabbut R. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. *Epilepsia* 2022; 63: 1349–97.
 36. Brown A, Raynor P, Lee M. Healthcare professionals' and mothers' perceptions of factors that influence decisions to breastfeed or formula feed infants: a comparative study. *Journal of advanced nursing* 2011; 67: 1993–2003.
 37. Services USDoAaUSDoHaH. Dietary Guidelines for Americans, 2020–2025. 9th Edition edn.: U.S. Department of Agriculture and U.S. Department of Health and Human Services; December 2020.
 38. von Geijer L, Ekelund M. Ketoacidosis associated with low-carbohydrate diet in a non-diabetic lactating woman: a case report. *Journal of medical case reports* 2015; 9: 224.
 39. Nnodum BN, Oduah E, Albert D, Pettus M. Ketogenic Diet-Induced Severe Ketoacidosis in a Lactating Woman: A Case Report and Review of the Literature. *Case reports in nephrology* 2019; 2019: 1214208.
 40. Alkhayat A, Arao K, Minami T, Manzoor K. Ketoacidosis associated with ketogenic diet in a non-diabetic lactating woman. *BMJ case reports* 2020; 13.
 41. Alsomali MA-O. Severe ketoacidosis in a lactating woman on a ketogenic diet. 2021.
 42. Habashy NS, Tan H, Hibbert EJ. The risk of ketogenic diets while breastfeeding: severe euglycaemic ketoacidosis. *The Medical journal of Australia* 2021; 215: 208–9 e1.
 43. Hong MJ, Schwartz LE, Ward HH, Morgan JC, Jacoby JL. Metabolic acidosis in a lactating woman induced by a deliberate ketogenic diet. *JAAPA: official journal of the American Academy of Physician Assistants* 2021; 34: 31–3.
 44. Osborne KC, Oliver JJ. Lactation ketoacidosis induced by breastfeeding while on a ketogenic diet. *The American journal of emergency medicine* 2022; 56: 392 e5- e6.
 45. Bravi F, Di Maso M, Eussen S, Agostoni C, Salvatori G, Profeti C, Tonetto P, Quitadamo PA, Kazmierska I, Vacca E, Decarli A, Stahl B, Bertino E, Moro GE, Ferraroni M, On Behalf Of The Medidiet Working G. Dietary Patterns of Breastfeeding Mothers and Human Milk Composition: Data from the Italian MEDIDIET Study. *Nutrients* 2021; 13.
 46. Gidrewicz DA, Fenton TR. A systematic review and meta-analysis of the nutrient content of preterm and term breast milk. *BMC pediatrics* 2014; 14: 216.
 47. Sahin S, Ozdemir T, Katipoglu N, Akcan AB, Kaynak Turkmen M. Comparison of Changes in Breast Milk Macronutrient Content During the First Month in Preterm and Term Infants. *Breastfeeding medicine: the official journal of the Academy of Breastfeeding Medicine* 2020; 15: 56–62.
 48. Lawrence RA, Lawrence RM. Chapter 4 - Biochemistry of Human Milk. In: Lawrence RA, Lawrence RM editors. *Breastfeeding (Seventh Edition)*. Philadelphia: W.B. Saunders; 2011. 98–152.
 49. Jenness R. The composition of human milk. *Seminars in perinatology* 1979; 3: 225–39.
 50. Ballard O, Morrow AL. Human milk composition: nutrients and bioactive factors. *Pediatric clinics of North America* 2013; 60: 49–74.
 51. Wu X, Jackson RT, Khan SA, Ahuja J, Pehrsson PR. Human Milk Nutrient Composition in the United States: Current Knowledge, Challenges, and Research Needs. *Current developments in nutrition* 2018; 2: nzy025.
 52. Kramer MS, Kakuma R. Optimal duration of exclusive breastfeeding. *The Cochrane database of systematic reviews* 2012; 2012: CD003517.
 53. Dieterich CM, Felice JP, O'Sullivan E, Rasmussen KM. Breastfeeding and health outcomes for the mother-infant dyad. *Pediatric clinics of North America* 2013; 60: 31–48.
 54. Shamir R. The Benefits of Breast Feeding. *Nestle Nutrition Institute workshop series* 2016; 86: 67–76.
 55. Perrella S, Gridneva Z, Lai CT, Stinson L, George A, Bilston-John S, Geddes D. Human milk composition promotes optimal infant growth, development and health. *Seminars in perinatology* 2021; 45: 151380.
 56. Kramer MS, Aboud F, Mironova E, Vanilovich I, Platt RW, Matush L, Igumnov S, Fombonne E, Bogdanovich N, Ducruet T, Collet JP, Chalmers B, Hodnett E, Davidovsky S, Skugarevsky O, Trofimovich O, Kozlova L, Shapiro S, Promotion of Breastfeeding Intervention Trial Study G. Breastfeeding and child cognitive development: new evidence from a large randomized trial. *Archives of general psychiatry* 2008; 65: 578–84.
 57. Belfort MB, Rifas-Shiman SL, Kleinman KP, Guthrie LB, Bellinger DC, Taveras EM, Gillman MW, Oken E. Infant feeding and childhood cognition at ages 3 and 7 years: Effects of breastfeeding duration and exclusivity. *JAMA pediatrics* 2013; 167: 836–44.
 58. Julvez J, Guxens M, Carsin AE, Fornis J, Mendez M, Turner MC, Sunyer J. A cohort study on full breastfeeding and child neuropsychological development: the role of maternal social, psychological, and nutritional factors. *Developmental medicine and child neurology* 2014; 56: 148–56.
 59. Tozzi AE, Bisiacchi P, Tarantino V, Chiarotti F, D'Elia L, De Mei B, Romano M, Gesualdo F, Salmaso S. Effect of duration of breastfeeding on neuropsychological development at 10 to 12 years of age in a cohort of healthy children. *Developmental medicine and child neurology* 2012; 54: 843–8.

60. Sun Y, Vestergaard M, Christensen J, Olsen J. Breastfeeding and risk of epilepsy in childhood: a birth cohort study. *The Journal of pediatrics* 2011; 158: 924–9.
61. Valentine CJ, Hurst Nm Fau - Schanler RJ, Schanler RJ. Hindmilk improves weight gain in low-birth-weight infants fed human milk. 1994.
62. Bishara R, Dunn MS, Merko SE, Darling P. Volume of foremilk, hindmilk, and total milk produced by mothers of very preterm infants born at less than 28 weeks of gestation. *Journal of human lactation: official journal of International Lactation Consultant Association* 2009; 25: 272–9.
63. Bishara R, Dunn MS, Merko SE, Darling P. Nutrient composition of hindmilk produced by mothers of very low birth weight infants born at less than 28 weeks' gestation. *Journal of human lactation: official journal of International Lactation Consultant Association* 2008; 24: 159–67.
64. Ogechi AA, William O, Fidelia BT. Hindmilk and weight gain in preterm very low-birthweight infants. *Pediatrics international: official journal of the Japan Pediatric Society* 2007; 49: 156–60.
65. Takumi H, Kato K, Nakanishi H, Tamura M, Ohto NT, Nagao S, Hirose J. Comprehensive Analysis of Lipid Composition in Human Foremilk and Hindmilk. *Journal of oleo science* 2022; 71: 947–57.
66. Armeno M, Verini A, Caballero E, Cresta A, Valenzuela GR, Caraballo R. Long-term effectiveness and adverse effects of ketogenic diet therapy in infants with drug-resistant epilepsy treated at a single center in Argentina. *Epilepsy research* 2021; 178: 106793.
67. Lin A, Turner Z, Doerrer SC, Stanfield A, Kossoff EH. Complications During Ketogenic Diet Initiation: Prevalence, Treatment, and Influence on Seizure Outcomes. *Pediatric neurology* 2017; 68: 35–9.
68. Furth SL, Casey JC, Pyzik PL, Neu AM, Docimo SG, Vining EP, Freeman JM, Fivush BA. Risk factors for urolithiasis in children on the ketogenic diet. *Pediatric nephrology* 2000; 15: 125–8.
69. Kielb S, Koo HP, Bloom DA, Faerber GJ. Nephrolithiasis associated with the ketogenic diet. *The Journal of urology* 2000; 164: 464–6.
70. Groesbeck DK, Bluml RM, Kossoff EH. Long-term use of the ketogenic diet in the treatment of epilepsy. *Developmental medicine and child neurology* 2006; 48: 978–81.
71. Paul E, Conant KD, Dunne IE, Pfeifer HH, Lyczkowski DA, Linshaw MA, Thiele EA. Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy. *Epilepsy research* 2010; 90: 151–6.
72. Ramantani G, Bolsterli BK, Alber M, Klepper J, Korinthenberg R, Kurlmann G, Tibussek D, Wolff M, Schmitt B. Treatment of Infantile Spasm Syndrome: Update from the Interdisciplinary Guideline Committee Coordinated by the German-Speaking Society of Neuropediatrics. *Neuropediatrics* 2022; 53: 389–401.
73. Pellock JM, Hrachovy R, Shinnar S, Baram TZ, Bettis D, Dlugos DJ, Gaillard WD, Gibson PA, Holmes GL, Nordl DR, O'Dell C, Shields WD, Trevathan E, Wheless JW. Infantile spasms: a U.S. consensus report. *Epilepsia* 2010; 51: 2175–89.
74. van Berkel AA, Dm IJ, Verkuyl JM. Cognitive benefits of the ketogenic diet in patients with epilepsy: A systematic overview. *Epilepsy & behavior: E&B* 2018; 87: 69–77.
75. Carroll JH, Cross JH, Hickson M, Williams E, Aldridge V, Collinson A. A core outcome set for childhood epilepsy treated with ketogenic diet therapy (CORE-KDT study): International parent and health professional consensus. *Epilepsia* 2023; 64: 919–36.
76. Kang HC, Lee Yj Fau - Lee JS, Lee Js Fau - Lee EJ, Lee Ej Fau - Eom S, Eom S Fau - You SJ, You Sj Fau - Kim HD, Kim HD. Comparison of short- versus long-term ketogenic diet for intractable infantile spasms. *Epilepsia* 2011.
77. Dority L. Breastfeeding Options and Ketogenic Diet Therapy (accessed 13.11.2023)

SUPPORTING INFORMATION

The following additional material may be found online:

Appendix S1: Questionnaire (2021) to assess the use of human milk and breastfeeding during KDT in infants with childhood epilepsy.

Appendix S2: Questionnaire (2023) to assess the use of human milk and breastfeeding during KDT in infants with childhood epilepsy.

Appendix S3: Testimonial.

Appendix S4: Ketogenic diet therapy, human milk, and breastfeeding pocket guide.

Figure S1: Summary of literature review for the use of KDT in infants including human milk and breastfeeding.

Table S1: Use of human milk and breastfeeding in infants while on KDT and strategies for using human milk and breastfeeding.

Table S2: Summary of nutritional recommendations for infants.

Table S3: Average macronutrient composition of human milk.

How to cite this article: van der Louw E, Trimmel-Schwahofer P, Devlin A, Armeno M, Thompson L, Cross JH, et al. Human milk and breastfeeding during ketogenic diet therapy in infants with epilepsy: Clinical practice guideline. *Dev Med Child Neurol.* 2024;00:1–13. <https://doi.org/10.1111/dmcn.15928>